Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11352350 IRAK degraders and uses thereof

Patent 11352350 was granted and assigned to Kymera Therapeutics on June, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Kymera Therapeutics

Current Assignee

Kymera Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

113523500

Patent Inventor Names

Xiaozhang Zheng0

Yi Zhang0

Nan Ji0

Nello Mainolfi0

Arthur F. Kluge0

Matthew M. Weiss0

Date of Patent

June 7, 2022

Patent Application Number

167010770

Date Filed

December 2, 2019

Patent Citations

‌

US Patent 10874743 IRAK degraders and uses thereof

‌

US Patent 10336744 1AP E3 ligase directed proteolysis targeting chimeric molecules

‌

US Patent 10125114 Methods to induce targeted protein degradation through bifunctional molecules

Patent Citations Received

‌

US Patent 12091411 IRAK degraders and uses thereof

‌

US Patent 11773103 IRAK4 degraders and uses thereof

‌

US Patent 11685750 Crystalline forms of IRAK degraders

Patent Primary Examiner

CPC Code

The present invention provides compounds, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11352350 IRAK degraders and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API